Insurance

Commercial formularies restrict access to lower-emission asthma and COPD inhalers

Commercial plans covered lower-emission inhalers less often and less favorably than metered-dose inhalers, the study found.

Reported by 2 outlets Monday, September 28, 2026

Orange prescription bottles and pills
Photo: CC0

A study published in JAMA Network Open found that commercial insurance formularies made lower-emission inhalers less accessible than metered-dose inhalers for people with asthma or chronic obstructive pulmonary disease. Researchers examined 31,219 commercial plans across the 50 states and Washington, D.C., in May 2026.

For short-acting β2-agonists, 66.4% of plans covered only a metered-dose inhaler, with no propellant-free option. Propellant-free versions were covered by 89.5% of plans for inhaled corticosteroids and 82.6% for inhaled corticosteroid and long-acting β2-agonist combinations. They were also less often covered on preferred tiers without prior authorization or step therapy. The researchers recommended that payers put at least one propellant-free option per class on preferred tiers while preserving access to metered-dose inhalers when clinically indicated. The analysis measured plan-level coverage, not individual enrollment or out-of-pocket costs.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.